news
Halozyme’s €2 billion bid to transform drug discovery
By acquiring Evotec, Halozyme aims to enhance drug discovery and delivery, driving substantial growth in the pharmaceutical sector.
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
news
FDA greenlights AI-developed drug targeting solid tumors
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
news
Breakthrough trial offers new hope for cystic fibrosis patients
A promising new inhaled therapy is progressing in Phase 2 trials, presenting new opportunities for improving cystic fibrosis treatment.
article
Biotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
news
Preventing F-actin build-up improves drosophila healthspan
Disrupting F-actin in aged brains restored brain autophagy to youthful levels and reversed some cellular markers of brain ageing.
news
p53’s role in ulcerative colitis and its progression to cancer
The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.
news
GPNMB: a potential therapeutic agent for cardiovascular disease
Researchers reveal that GPNMB could be an effective therapeutic agent to improve cardiac function and prevent heart failure.
article
Harnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
article
Cell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
news
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
article
AI-driven drug discovery: insights from Cresset
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
news
Largest biobank of sarcoma-patient-derived organoids to date
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
news
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
news
BCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
article
’1104: tackling the root cause of allergic disease
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
